Migraine drug satisfaction study ends early – what did we learn?
NCT ID NCT06237062
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 37 migraine patients in the Gulf region who had just started taking erenumab. Researchers measured how satisfied patients were with the treatment over 12 weeks using a questionnaire. The study was observational, meaning patients received their normal care, and was terminated early, so findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
erenumab
What this could lead to
If successful, this could show that erenumab improves treatment satisfaction for migraine patients in real-world settings.
What could go wrong
This was a small, terminated observational study with only 37 participants, so results may not be reliable or generalizable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.